Company Overview
| Stock Name | Innocare |
|---|---|
| Stock Code | 09969 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 我們是一家處於臨床階段的生物醫藥公司,致力於發現、研發及商業化潛在同類最佳及/或首創的用於治療癌症及自身免疫性疾病的藥物。 |
| Listing Date | 2020-03-23 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 中國 北京市 昌平區 中關村生命科學園 生命園路8號院8號樓 |
| Business Address (Hong Kong) | 香港 灣仔 皇后大道東248號 陽光中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.innocarepharma.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | Mechanism A |
|---|---|
| Offer Price | HK$ 8.95 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | To be extracted |
| Entry Threshold | To be extracted |
| Par Value | To be extracted |
| Offer Period | 2020-03-11 to 2020-03-16 |
| Global Offering Shares | 250,324,000 shares |
| HK Public Offer Shares (Initial) | 25,034,000 shares (10.0%) |
| Public Offer Lots (Initial) | To be extracted |
| International Placing Shares (Initial) | 225,290,000 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 1,251,617,235 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 50.0% |
| Clawback Tiers | To be extracted |
| Reallocation Option | Yes |
| Total Global Offering Size | HK$ 2,240,399,800 |
Stock Connect Inclusion Analysis
| HK Market Cap | HK$ 19.05B |
|---|---|
| Analysis Result | Already included in Stock Connect (both) |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 11,201,974,253 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 亏损人民币554.0百万元 |
| Period-End Cash Balance | 人民币1876.6百万元 |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
RMB
Income Statement
| Item | 2018 | 2019 |
|---|---|---|
| Revenue | 1,617 | 1,247 |
| Cost of sales | 0 | 0 |
| Gross profit | 1,617 | 1,247 |
| Other income and gains, net | 31,395 | 104,449 |
| Selling and distribution expenses | -558 | -3,458 |
| Administrative expenses | -17,523 | -63,623 |
| Net finance costs | -3,441 | -1,916 |
| Share of associates and JVs | -4 | 0 |
| Profit before tax | -554,023 | -2,150,351 |
| Income tax expense | 0 | 0 |
| Profit for the year | -554,023 | -2,150,351 |
| Profit attributable to owners | -549,950 | -2,141,388 |
Balance Sheet
| Item | 2018 | 2019 |
|---|---|---|
| Cash and cash equivalents | 1,876,618 | 2,291,773 |
| Trade and bills receivables | 44 | 37 |
| Total current assets | 2,063,504 | 2,408,747 |
| Total current liabilities | 72,289 | 65,672 |
| Total equity | -838,374 | -2,947,746 |
| Equity attributable to owners | -904,301 | -3,004,710 |
| Interest-bearing borrowings | 1,007,664 | 1,117,176 |
Cash Flow Statement
| Item | 2017 | 2018 | 2019-09 |
|---|---|---|---|
| Net cash from operating activities | -49,356 | -17,677 | |
| Net cash from investing activities | 25,173 | -888,109 | |
| Net cash from financing activities | 26,810 | 2,101,300 | |
| Net increase in cash | 2,627 | 1,195,514 | |
| Depreciation of PP&E | 552 | 1,078 | 1,080 |
| Depreciation of right-of-use assets | 3,149 | 4,219 | 5,039 |
| Amortisation of intangible assets | 17 | 91 | 355 |
| Purchase of PP&E | -1,417 | -3,624 | -10,990 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 9.81 |
|---|---|
| First Day Open | HK$ 9.4 |
| First Day Change | 9.61% |
| First Day Volume | 115988000.0 |
| First Day Turnover | 1148180000.0 |
| Use of Proceeds | 1、預期約1,046.54百萬港元(相當于所得款項凈額的50.0%)將用作為奧布替尼同時在中國及美國正在進行和計劃進行的臨床試驗、準備注冊文件及潛在的商業推出(包括銷售和營銷)提供資金;
2、預期約523.27百萬港元(相當于所得款項凈額的25.0%)將用作為我們的兩個臨床階段候選產品提供資金;
3、預期約313.96百百萬港元(相當于所得款項凈額的15.0%)將用作為我們管線中的六種IND準備階段的候選藥物的研發以及新候選藥物的研發及外部引進提供資金;
4、預期約209.31百萬港元(相當于所得款項凈額的10.0%)將用作我們的營運資金及其他一般企業用途。 |
Underwriting Syndicate
Overall Coordinators (4)
Joint Bookrunners (6)
Joint Lead Managers (6)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Athos Asia Event Driven Master Fund | 68,306,400 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 2 | Golden Valley Global Limited | 34,153,200 HKD | — | 1.52% | — | 6 months | 2020-09-23 |
| 3 | Hankang Biotech Fund I, L.P. | 68,297,450 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 4 | Matthews Asia Funds | 157,108,300 HKD | — | 7.01% | — | 6 months | 2020-09-23 |
| 5 | Octagon Investments Master Fund LP | 40,991,000 HKD | — | 1.83% | — | 6 months | 2020-09-23 |
| 6 | Orient Sun Rise Global Superior Choice SPC | 68,297,450 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 7 | Rock Springs Capital Master Fund LP | 68,306,400 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 8 | Tiger Pacific Master Fund LP | 102,459,600 HKD | — | 4.57% | — | 6 months | 2020-09-23 |
| 9 | Vivo Funds | 170,766,000 HKD | — | 7.62% | — | 6 months | 2020-09-23 |
| 10 | WT Investment Management | 68,297,450 HKD | — | 3.05% | — | 6 months | 2020-09-23 |
| 11 | 妙城集团有限公司 | 34,153,200 HKD | — | 1.52% | — | 6 months | 2020-09-23 |
| 12 | 中国国有企业结构调整基金股份有限公司 | 239,063,450 HKD | — | 10.67% | — | 6 months | 2020-09-23 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 崔霽松 | — |
| Company Secretary | 楊靜文 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 崔霽松博士及直系家族成員持股約11.38%(上市後),趙仁濱博士及直系家族成員持股約12.43%,TMF (Cayman) Ltd.持股約10.91%,GIC Private Limited持股約9.54%,Vivo Capital VIII, LLC持股約6.80%,LVC實體持股約9.66%,Hebert Pang Kee Chan持股約12.89%。 |
|---|




